Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women
University of Washington · Fred Hutch Cancer Center · +20 more institutions
Abstract
Antiretroviral medications that are used as prophylaxis can prevent acquisition of human immunodeficiency virus type 1 (HIV-1) infection. However, in clinical trials among African women, the incidence of HIV-1 infection was not reduced, probably because of low adherence. Longer-acting methods of drug delivery, such as vaginal rings, may simplify use of antiretroviral medications and provide HIV-1 protection.
We conducted a phase 3, randomized, double-blind, placebo-controlled trial of a monthly vaginal ring containing dapivirine, a non-nucleoside HIV-1 reverse-transcriptase inhibitor, involving women between the ages of 18 and 45 years in Malawi, South Africa, Uganda, and Zimbabwe.
Citation impact
- FWCI
- 75.77
- Percentile
- 100%
- References
- 30
Authors
52- JMJared M. BaetenCorresponding
University of Washington, Fred Hutch Cancer Center
- TPThesla Palanee‐Phillips
University of the Witwatersrand, Fred Hutch Cancer Center
- ERElizabeth R. Brown
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa, University of Washington, Fred Hutch Cancer Center, Cancer Research Center
- KSKatie Schwartz
Family Health International 360, Johns Hopkins University, Fred Hutch Cancer Center
- LSLydia Soto‐Torres
Johns Hopkins University, Fred Hutch Cancer Center, National Institute of Allergy and Infectious Diseases
Topics & keywords
- Medicine
- Incidence (geometry)
- Vaginal ring
- Placebo
- Confidence interval
- Gynecology
- Internal medicine
- Reverse-transcriptase inhibitor
- Good health and well-being